Pharma

Your Article Summary

See Latest Articles

U.S. Patent and Trademark Office Accepts Pfizers Reissue Application on Lipitor Enantiomer Patent
Pfizer, 01/08/09

Pfizer Inc announced that the U.S. Patent & Trademark Office has issued a "Notice of Allowance" accepting the company's application to correct the technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form of atorvastatin sold as Lipitor. The company noted that certain formalities must be completed before the reissue patent will be granted. The reissued patent will have the same force and effect as the original '995 patent and the same June 2011 expiration date (including the six-month pediatric exclusivity period).

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

Mylan Receives Approval for Generic Version of Antiepileptic Keppra 1000 mg
Mylan, 12/15/09

 See all of Drug/Product Approvals